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Abstract
Background: Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that
is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density
lipoprotein cholesterol (LDLC) by negatively regulating low density lipoprotein receptor (LDLR)
levels. PCSK9 variants that result in 'gain of function' have been linked to autosomal dominant
hypercholesterolemia, while significant protection from coronary artery disease has been
documented in individuals who carry 'loss of function' PCSK9 variants. PCSK9 circulates in human
plasma, and we previously reported that plasma PCSK9 is positively correlated with total
cholesterol and LDLC in men.
Results: Herein, we report the effects of two lipid-modulating therapies, namely statins and
fibrates, on PCSK9 plasma levels in human subjects. We also document their effects on endogenous
PCSK9 and LDLR expression in a human hepatocyte cell line, HepG2, using immunoprecipitation
and immunoblot analyses. Changes in plasma PCSK9 following fenofibrate or gemfibrozil
treatments (fibric acid derivatives) were inversely correlated with changes in LDLC levels (r = -
0.558, p = 0.013). Atorvastatin administration (HMGCoA reductase inhibitor) significantly
increased plasma PCSK9 (7.40%, p = 0.033) and these changes were inversely correlated with
changes in LDLC levels (r = -0.393, p = 0.012). Immunoblot analyses of endogenous PCSK9 and
LDLR expression by HepG2 cells in response to statins and fibrates showed that LDLR is more
upregulated than PCSK9 by simvastatin (2.6× vs 1.5×, respectively at 10 μM), while fenofibrate did
not induce changes in either.
Conclusion: These results suggest that in vivo (1) statins directly increase PCSK9 expression while
(2) fibrates affect PCSK9 expression indirectly through its modulation of cholesterol levels and (3)
that these therapies could be improved by combination with a PCSK9 inhibitor, constituting a novel
hypercholesterolemic therapy, since PCSK9 was significantly upregulated by both treatments.
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Background
Proprotein convertase subtilisin/kexin-like 9 (PCSK9) [1] is a
highly polymorphic gene with over 40 non-synonymous,
exonic single nucleotide polymorphisms (SNPs) reported
in humans [2]. Three of these PCSK9 variants cause auto-
somal dominant hypercholesterolemia (ADH) [3-6]
while 11 others associate with a hypercholesterolemic
phenotype [2]. In addition, two nonsense and several mis-
sense PCSK9 variants were reported that associated with
hypocholesterolemia [7-9]. Thus, PCSK9 variants result-
ing in a 'gain-of-function' predispose carriers to hypercho-
lesterolemia, whereas PCSK9 variants resulting in a 'loss-
of-function' associate with hypocholesterolemia. Studies
that have shown decreased risk of coronary artery disease
for 'loss-of-function' PCSK9 carriers have generated great
interest in the development of PCSK9 inhibitors that
could improve current dyslipidemic therapies [7,10,11].
PCSK9 transcription is upregulated by the cholesterogenic
pathway through sterol regulatory element binding pro-
tein-2 (SREBP-2) [12-14], a transcription factor important
for the regulation of genes involved in cholesterol biosyn-
thesis as well as low density lipoprotein receptor (LDLR)
synthesis. PCSK9 is most highly expressed in the liver and
small intestine, and is found in circulation [15-17].
Secreted PCSK9 can interact with cell surface LDLR and
enter the endocytic recycling pathway, shifting the equi-
librium of LDLR recycling toward LDLR lysosomal-
dependent degradation, thereby modifying circulating
low density lipoprotein cholesterol (LDLC) levels [16,18-
22].
Recently we reported that plasma PCSK9 levels correlated
to total cholesterol (TC) and LDLC in men but not in
women, and that plasma PCSK9 levels may be an indica-
tor of carriers of PCSK9 variants [17]. Since PCSK9 is a tar-
get for drug design, to improve current dyslipidemic
therapies, it is important to understand how current treat-
ments affect PCSK9 expression. We report here on the
effects of two classes of lipid-lowering drugs (fibrates and
statins) on plasma PCSK9 levels and their effect on PCSK9
and LDLR expression in a hepatic cell line. Collectively,
our results show that: (1) plasma and secreted PCSK9 lev-
els reflect intracellular levels of PCSK9, (2) changes in
LDLC are associated with changes in circulating levels of
this enzyme and (3) by monitoring plasma PCSK9
changes during dyslipidemic therapies one can identify
those individuals that would benefit most from combina-
tion therapy with PCSK9 inhibitors.
Results
The level of fasting PCSK9 in human plasma is affected by 
fibrate therapy
Fibrates primarily reduce triglycerides (TG) and increase
high density lipoprotein cholesterol (HDLC) levels with
variable effects on LDLC [23]. Using samples from a study
that compared the efficacy of two standard fibrate thera-
pies [24], we measured plasma PCSK9 levels from 19 indi-
viduals (12 men and 7 women) pre- and post-fibrate
treatment. We did not observe any significant difference
in pre-treatment lipids between the fenofibrate (n = 9)
and gemfibrozil (n = 10) groups or in lipoprotein param-
eters in response to treatments between the two groups
(data not shown). Therefore these subjects were com-
bined and further analyzed as the fibrate group (n = 19;
Table 1). The average pre- and post-treatment levels, as
well as percent change in PCSK9, TC, LDLC, TG, HDLC
and the TC/HDLC ratio are shown in Table 1. Total cho-
lesterol, TG and the TC/HDLC ratio significantly
decreased following fibrate therapy (-11.3%; p = 0.002, -
43.6%; p < 0.0001 and -22.0%; p < 0.0003, respectively),
while plasma PCSK9 and HDLC increased significantly
(17.0%; p = 0.031 and 15.7%; p = 0.002 respectively).
Although LDLC did not show a significant change with
therapy, it should be noted that 8 individuals showed an
increase while 11 individuals showed a decrease in LDLC.
We went on to examine the relationship between the per-
cent change in PCSK9 and lipoprotein parameters pre-
and post-therapy using Spearman's correlation. There was
a significant inverse correlation between changes in the
levels of PCSK9 and LDLC (Fig 1; r = -0.558, p = 0.013, n
= 19), attributable to the significant association between
these two parameters in men (r = -0.622, p = 0.031, n =
12).
The level of PCSK9 and LDLR in the HepG2 cell line is 
unaffected by fibrates
Figure 2 represents the regulation of the intracellular
proPCSK9 and intracellular mature PCSK9 (mPCSK9),
secreted PCSK9 (sPCSK9) and the LDLR (A to C, respec-
tively), in response to increasing concentrations of fenof-
ibrate (0–200 μM). The amount of proPCSK9 and
mPCSK9 (panel A) did not change significantly, nor did
sPCSK9 (panel B). As well, there was no significant
response in LDLR expression over these concentrations of
fenofibrate (panel C). These data indicate that fenofibrate
treatment does not directly affect PCSK9 or LDLR expres-
sion in HepG2 cells.
The level of fasting PCSK9 in human plasma is affected by 
statin therapy
Statin therapy lowers LDLC levels by inhibiting hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCoAR),
abating intracellular cholesterol levels while increasing
the expression of the LDLR [25]. This serves to augment
clearance of circulating LDLC through increased liver
uptake [25]. To examine the effect of statin therapy on
PCSK9, we measured its level from the serum of 40 indi-
viduals from a study comparing lipid parameters pre- and
post-atorvastatin treatment. The average pre- and post-Lipids in Health and Disease 2008, 7:22 http://www.lipidworld.com/content/7/1/22
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treatment levels, and percent change for PCSK9, TC,
LDLC, TG, HDLC and the TC/HDLC ratio are shown in
Table 2. Atorvastatin significantly reduced TC, LDLC and
TG levels (-25.0%; p < 0.0001, -38.0%; p < 0.0001 and -
16.2%; p < 0.001, respectively) while significantly increas-
ing HDLC levels (8.03%; p < 0.0001). Plasma PCSK9 lev-
els significantly increased by 7.40% (p = 0.035). Changes
in plasma PCSK9 levels following atorvastatin therapy
showed a significant inverse relationship with changes in
LDLC (Fig 3; r = -0.393, p = 0.012, n = 40), which was
attributable to the strong association between these two
parameters in men (r = -0.488, p = 0.005, n = 31).
The levels of PCSK9 and LDLR in the HepG2 cell line are 
affected by statin therapy
Figure 4 represents the upregulation, at the protein level,
of the intracellular and secreted forms of PCSK9 (A and B,
respectively) and the LDLR (C) in response to increasing
concentrations of simvastatin (0–10 μM). Significant
upregulation of proPCSK9 as well as mPCSK9 was
observed at 1 μM simvastatin when compared to
untreated control cells (panel A). The same trend was
observed with sPCSK9 although this did not reach signif-
icance (panel B). The ratio of proPCSK9 to mPCSK9 did
not change significantly upon upregulation. As well,
upregulation of intracellular PCSK9 was reflected by
changes in secreted PCSK9 measurements (compare pan-
els A and B). The LDLR was also significantly upregulated
by simvastatin at 1 μM, showing a 2× increase compared
to untreated control cells (panel C). From 1–10 μM simv-
astatin, LDLR expression was more highly upregulated
than intracellular and secreted PCSK9; compare 2.6× to
1.5× and 1.5×, respectively (Fig 4).
Discussion
In previous reports we showed that PCSK9 is efficiently
secreted from HepG2 cells [1]. Herein, we show that
changes in secreted PCSK9 reflect changes in intracellular
PCSK9 expression in a HepG2 cell model (Figs 2 and 4).
This direct link between maturation of proPCSK9 to
mPCSK9 and its secretion further suggests, along with our
published association of 'loss of function' PCSK9 variants
with reduced levels of plasma PCSK9 [17], that plasma
levels of PCSK9 can serve as a measure of regulation of
this physiologically relevant PCSK in humans.
This study demonstrates that plasma PCSK9 levels are sig-
nificantly modified by two common lipid therapies;
fibrates and statins (Tables 1 and 2 and Figs 1 and 3). The
effect of fibrate therapy on plasma PCSK9 levels has not
been previously reported. Fibrates (peroxisome prolifera-
tor activated receptor alpha (PPARα) agonists) are a class
of drug that is used to primarily treat hypertriglyceridemia
and low HDLC. They induce the PPARα pathway and
upregulate genes that encode proteins that increase HDL
production and secretion, while reducing very low-den-
sity lipoprotein (VLDL) triglyceride secretion [26].
Fibrates have variable effects on circulating LDLC levels
through an unknown pathway [26]. Indeed in our cohort
of patients (n = 19); 8 individuals showed an increase,
while 11 individuals showed a decrease in LDLC levels
following fibrate therapy (Fig 1). Likewise, the levels of
plasma PCSK9 both increased and decreased following
fibrate treatment; overall, however there was a significant
increase in plasma PCSK9 levels of 17% (Table 1 and Fig
1). As well, changes in plasma PCSK9 were significantly
inversely correlated to changes observed in LDLC follow-
ing fibrate therapy (Fig 1).
Our cell culture data indicated that fenofibrate (up to 200
μM) does not significantly change the expression of
PCSK9 or the LDLR (Fig 2). A recent report suggests that
PCSK9 mRNA expression can be significantly repressed in
HepG2 cells by fenofibrate at concentrations >200 μM
[27]. Similar to this study we also see non-significant
Table 1: Fasting PCSK9 and lipid levels pre- and post-fibrate 
treatment
Baseline Treatment % Change
PCSK9 (μg/mL) 6.04 ± 1.10 6.90 ± 1.38* 17.01 ± 29.5
Total cholesterol 6.22 ± 0.73 5.50 ± 0.88** -11.3 ± 11.6
Triglycerides 3.27 ± 0.59 1.85 ± 0.80*** -43.6 ± 22.8
HDL cholesterol 0.86 ± 0.13 1.00 ± 0.21** 15.7 ± 18.4
LDL cholesterol 3.85 ± 0.65 3.65 ± 0.71 -4.22 ± 17.6
TC/HDLC Ratio 7.35 ± 1.22 5.79 ± 1.68*** -22.0 ± 13.5
Significance comparing baseline and treatment by Wilcoxon's signed 
rank test (n = 19). Values expressed as μmol/L except where 
indicated.
*p < 0.05, **p < 0.001, ***p < 0.0001 Relationship between percent change in plasma PCSK9 and  LDL-cholesterol levels following fibrate treatment Figure 1
Relationship between percent change in plasma 
PCSK9 and LDL-cholesterol levels following fibrate 
treatment. PCSK9 and LDL-C were measured pre- and 
post-fibrate therapy as described in Methods. Pre-treatment 
levels were set as 100%.
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Effect of increasing concentrations of fenofibrate on PCSK9 and LDLR protein expression in HepG2 cells Figure 2
Effect of increasing concentrations of fenofibrate on PCSK9 and LDLR protein expression in HepG2 cells. Cells 
were grown in DMEM + 10% FBS and supplemented with increasing concentrations of fenofibrate for 24 hours at 37°C. 50 μg 
of total cell lysates (A and C) and 100 μl cell media (B) were analyzed by immunoblotting (IB), or immunoprecipitation (IP) fol-
lowed by IB, respectively, as described in Methods. A and B were IB with anti-hPCSK9 Ab and C with anti-hLDLR Ab. The pro-
tein signals were quantified by densitometry using Syngene Chemigenius 2XE imager and Gene Tools software. All values were 
made relative to values from untreated cells set as 1 and presented as mean ± SEM (n = 3).
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downregulation of PCSK9 protein levels at 200 μM but
not at lower concentrations. It is important to note that
based on the pharmacokinetics for gemfibrozil [28] and
fenofibrate [29] in humans, the subjects in our study
received 100 μM and 30 μM, respectively, well below that
reported to repress PCSK9  transcription  ex vivo. Taken
together with our data from human studies (Fig 1), it is
likely that therapeutic doses of fibrates exert their effect on
plasma levels of PCSK9 indirectly, in response to changes
in cholesterol levels. We suggest that in the case of
increased levels of circulating LDLC, intracellular levels of
sterols increase, downregulating genes activated by the
SREBP pathway (including PCSK9) and vice versa.
PCSK9  is upregulated by cellular cholesterol depletion
through the sterol regulatory element binding protein-2
(SREBP-2) pathway [14]. The SREBP family includes three
transcription factors, SREBP-1a, -1c and -2. SREBP-2 pref-
erentially activates genes involved in cholesterol biosyn-
thesis and metabolism, such as HMGCoA synthase and
HMGCoAR. SREBPs -1a and -1c preferentially activate
genes involved in fatty acid biosynthesis, such as acetyl
CoA carboxylase and ATP citrate lyase [30]. The role of
SREBP-2 in PCSK9 transcriptional regulation is well docu-
mented [12-14,31] while several reports suggest that
PCSK9 is also regulated by SREBP-1c [12,13,32]. Statins
inhibit HMGCoAR, a rate-limiting enzyme in cholesterol
biosynthesis and have been shown to significantly
increase PCSK9 mRNA in HepG2 cells and primary
human hepatocytes through activation of the SREBP-2
pathway [14].
In this report, we measured plasma PCSK9 levels in
response to low-dose atorvastatin therapy (10 mg/day)
and show an average increase of 7.4% in circulating levels
of PCSK9 in individuals following treatment (effective
dosage 0.0217 μM). Another group showed that 40 mg/
day atorvastatin further increased plasma PCSK9 by 34%
[33]. However, they did not report the significant inverse
correlation between percent change in LDLC and PCSK9
that we observed (Fig 3). This may be because their study
group was smaller (n = 12 versus n = 40). The results we
report here for protein upregulation of PCSK9 by simvas-
tatin in HepG2 cells (Fig 4; 40% at 0.05 μM) was compa-
rable to that observed in their study undergoing
atorvastatin therapy (34% at 0.08 μM). Collectively, our
cell culture and human studies suggest that in response to
statins, increases in PCSK9 mRNA levels are reflected in
circulating levels of PCSK9 (Fig 3).
Statins reduce LDLC levels through a second mechanism;
they increase LDLR levels through the SREBP-2 pathway,
further decreasing circulating LDLC. PCSK9, which can
degrade the LDLR, is also upregulated by statins in vivo
(Fig 3) and ex vivo (Fig 4). When we measured the effect of
simvastatin on the LDLR protein expression in the HepG2
cell line, it showed significant upregulation at 1 μM (Fig
4). However, LDLR expression was more highly upregu-
lated than that of PCSK9 (2.0× versus 1.5× at 1 μM and
2.6× versus 1.5× at 10 μM simvastatin, respectively). This
suggests that although PCSK9 is a negative regulator of the
LDLR and, in the case of statins, is upregulated in concert
with the LDLR by the SREBP-2 pathway, the increase in
PCSK9 at the protein level is not sufficient to completely
negate upregulation of the LDLR.
In our study the average increase in plasma PCSK9 was
greater following fibrate therapy (17%) than following
statin therapy (7%). These two post-hoc study groups are
exclusive in terms of participants; therefore, we cannot
directly compare differences in responses between the two
therapies. However, we do know that an increase in
Table 2: Fasting PCSK9 and lipid levels pre- and post-
atorvastatin treatment
Baseline Treatment % Change
PCSK9 (μg/mL) 5.88 ± 1.70 6.32 ± 2.29* 7.40 ± 25.3
Total cholesterol 5.82 ± 0.76 4.37 ± 0.62*** -25.0 ± 9.06
Triglycerides 1.50 ± 0.56 1.26 ± 0.58** -16.2 ± 28.0
HDL cholesterol 1.32 ± 0.26 1.43 ± 0.30*** 8.03 ± 13.2
LDL cholesterol 3.82 ± 0.67 2.37 ± 0.53*** -38.0 ± 10.3
TC/HDLC Ratio 4.53 ± 0.89 3.17 ± 0.63*** -30.1 ± 9.79
Significance comparing baseline and treatment by Wilcoxon's signed 
rank test (n = 40). Values expressed as μmol/L except where 
indicated.
*p < 0.05, **p < 0.001, ***p < 0.0001
Relationship between percent change in plasma PCSK9 and  LDL-cholesterol levels following statin treatment Figure 3
Relationship between percent change in plasma 
PCSK9 and LDL-cholesterol levels following statin 
treatment. PCSK9 and LDL-C were measured pre- and 
post-statin therapy as described in Methods. Pre-treatment 
levels were set as 100%.
r = - 0.017, p = 0.966, n = 9 (women     )
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Effect of increasing concentrations of simvastatin on PCSK9 and LDLR expression in HepG2 cells Figure 4
Effect of increasing concentrations of simvastatin on PCSK9 and LDLR expression in HepG2 cells. HepG2 cells 
were grown in DMEM + 10% FBS and supplemented with increasing concentrations of simvastatin for 24 hours at 37°C. 50 μg 
of total cell lysates (A and C) and 100 μl cell media (B) were analyzed by immunoblotting (IB), or immunoprecipitation (IP) fol-
lowed by IB, respectively, as described in Methods. A and B were IB with anti-hPCSK9 Ab and C with anti-hLDLR Ab. The pro-
tein signals were quantified by densitometry using Syngene Chemigenius 2XE imager and Gene Tools software. All values were 
made relative to values from untreated cells set as 1 and presented as mean ± SEM (n = 3). * Indicates significant differences 
from untreated control (p < 0.05) using student's T-test.
B
R
e
l
a
t
i
v
e
 
A
m
o
u
n
t
10
1.0 1.0
1.4 1.5 1.6 1.5
0.0
0.5
1.0
1.5
2.0
0 0.01 0.05 1 5 10
1.0 1.0
1.4 1.5 1.6 1.5
0.0
0.5
1.0
1.5
2.0
0 0.01 0.05 1 5 10
sPCSK9
R
e
l
a
t
i
v
e
 
A
m
o
u
n
t
2.0 * * *
1.0 1.1 1.1
1.6 1.7 1.8
1.0 1.0 1.0
1.3 1.4 1.5
0.0
0.5
1.0
1.5
0 0.01 0.05 1 5 10
* * *
mPCSK9
ProPCSK9
Non- specific
A
C
R
e
l
a
t
i
v
e
 
A
m
o
u
n
t
2.6
1.0 1.1 1.1
2.0
2.6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 0.01 0.05 1 5 10
*
2.6
1.0 1.1 1.1
2.0
2.6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.01 0.05 1 5 10
2.6 2.6
1.0 1.1 1.1
2.0
2.6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.01 0.05 1 5 10
1.0 1.1 1.1
2.0
2.6
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.01 0.05 1 5 10
Simvastatin μM
LDLR
* *Lipids in Health and Disease 2008, 7:22 http://www.lipidworld.com/content/7/1/22
Page 7 of 9
(page number not for citation purposes)
PCSK9 may limit the efficacy of therapies in terms of low-
ering circulating LDLC levels.
In both fibrate and statin cohorts, the inverse correlation
between changes in plasma PCSK9 and LDLC was signifi-
cant in men, and not in women, although the numbers of
women were low and therefore may not have been signif-
icantly powered. Previously we reported a gender dichot-
omy in the direct relationship between LDLC levels and
plasma PCSK9 in men and not women [17], suggesting
that gender-specific hormones such as estrogens and/or
testosterone may also affect PCSK9 transcription and/or
expression. This is an avenue we are pursuing.
Conclusion
This study demonstrates that plasma PCSK9 can be used
as an accessible and meaningful measurement of its intra-
cellular regulation. This provides useful information, such
as identifying those individuals that would benefit most
from combination therapy with PCSK9 inhibitors (now
being developed) that could improve current dyslipi-
demic therapies. In conclusion, since PCSK9 was signifi-
cantly upregulated by both fibrate and statin therapies,
our results indicate that individuals undergoing either
treatment (even at low doses) may benefit by combina-
tion with PCSK9 inhibitors, increasing their LDLC lower-
ing effect.
Methods
Antibodies
The anti-PCSK9 antibody used for immunoprecipitation
(anti-native PCSK9 Ab) was raised in rabbits by human
PCSK9 cDNA vaccination [34]. The anti-PCSK9 antibody
used for immunoblotting (anti-IB PCSK9 Ab; (provided
by N.G. Seidah) was produced by recombinant PCSK9
vaccination [17]. The anti-LDLR antibody was purchased
from Research Diagnostics. Secondary HRP-conjugated
antibodies were purchased from Amersham.
Cell culture and sample collection
HepG2 cells were grown at 37°C in DMEM + 10% FBS +
gentamycin 28 μg/mL. For dose response experiments,
media was supplemented with a modifier, and cells cul-
tured for an additional 24 hours. Modifiers included sim-
vastatin (0–10 μM; provided by Z. Yao) and fenofibrate
(0–200 μM; Sigma). Media was collected in the presence
of protease inhibitor cocktail (PIC; Roche). Cells were
lysed in 1× RIPA (50 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 1% (v/v) NP-40, 0.5% deoxycholate (w/v), 0.1%
(w/v) sodium dodecyl sulfate (SDS), PIC) at 4°C for 20
min. Samples were centrifuged at 13,000 × g for 10 min
and total cell lysates (TCL) collected. Protein concentra-
tions were determined by BioRad Protein Assay.
Immunoprecipitation and immunoblotting
Immunoprecipitations (IP) of PCSK9 from cell culture
media were carried out following standard protocols with
excess anti-native PCSK9 Ab (1:500) and 25 μl of Protein-
A agarose (Sigma) overnight at 4°C. Immunoprecipitates
and TCL were immunoblotted (IB) following standard
protocol. The primary anti-IB PCSK9 was used at 1/1000,
the anti-LDLR was used at 1/250 and the secondary anti-
bodies at 1/5000 dilutions. Immunoblots were revealed
by chemiluminescence (Western Lightening Plus; Perkin-
Elmer) on X-OMAT film (Kodak). The PCSK9 signal was
quantified by densitometry using Syngene's Chemigenius
2XE imager and GeneTool software. Experiments were
carried out in triplicate.
Subjects, sample handling and assay procedures
For human studies described below all 59 subjects gave
informed written consent and the ethics research commit-
tees approved study protocols. The fibrate treatment
group included 19 subjects (12 males and 7 females) from
a post-hoc study who were recruited from the Ottawa
Hospital Lipid Clinic and given fibrate therapy [24]. Sub-
jects were required to have a TC/HDLC ratio ≥ 6.0 for
males, 5.6 for females and elevated TGs (2.3–5.5 mmol/
L). They were on the American Heart Association/
National Cholesterol Education Program Step 1 diet 4–8
weeks prior to receiving fibrates and were not taking lipid-
lowering medication. As part of a comparison study for
efficacy of fibrates, nine subjects had received 67 mg
micronized fenofibrate 3× daily for 24 ± 3 weeks and 10
subjects had received 600 mg gemfibrozil 2× daily for 24
± 3 weeks, both standard treatment regimes. Blood was
collected pre- and post-treatment. Plasma was obtained
from blood collected into vacutainer tubes containing
EDTA for the fasted fibrate group. TC and TG were meas-
ured using enzymatic kits (Boehringer Mannheim)
adapted for a Roche Cobas Mira analyzer. HDLC was
measured in the supernatant following precipitation of
non-HDLC with phosphotungstate on BM/Hitachi 917
analyzer (Roche Diagnostics) and LDLC was calculated as
above.
The statin treatment group included forty subjects (31
males and 9 females) from a post-hoc study who were
recruited to the Vascular Disease Prevention and Research
Centre at the Southeastern Ontario Health Sciences Cen-
tre in Kingston (n = 33) or the Ottawa Hospital Lipid
Clinic (n = 7). Subjects were required to have elevated
LDLC (≥ 3.0 mmol/L). They discontinued all lipid-lower-
ing medication for 4 weeks prior to commencement of
atorvastatin to establish baseline levels. Subjects then
received a standard 10 mg atorvastatin dose once daily for
6 weeks. Blood was collected pre- and post-treatment.
Serum was obtained from blood collected into SST vacu-
tainer tubes for the fasted atorvastatin group. TC, TG andLipids in Health and Disease 2008, 7:22 http://www.lipidworld.com/content/7/1/22
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HDLC were measured using Roche test kits on the Roche
Modular Instrument. LDLC was calculated by the Friede-
wald equation.
For post-hoc studies of changes in plasma PCSK9 levels
from our statin and fibrate groups the plasma PCSK9
assay was carried out as per Mayne et al [17]. All samples
were quantified a minimum of 2× with an intra-assay
coefficient of variability (CV) of 6.4% and an interassay
CV of 7.3%.
Statistical analysis
All results are expressed as mean ± standard deviation
(SD), except where indicated. The differences in lipid
parameters between the fenofibrate and gemfibrozil
groups were analyzed by Mann-Whitney U test. Pre- and
post-treatment data within each treatment group were
compared using the Wilcoxon's signed rank test. Spear-
man correlation coefficients (r) were determined to assess
the relationship between different parameters. Data was
analyzed using SAS/PC statistical software and GraphPad
Prism 5.0 with significance defined as p < 0.05.
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